Preserved to preservative free prostaglandin analogues in primary open angle glaucoma

Asha S. Morge, M. D. Kulkarni, S. M. Doifode

Abstract


Glaucoma affecting 60 million people all over the world and it will be 80 million till 2020. There are approximately 11.2 million persons aged 40 years and older with glaucoma in India. Primary open angle glaucoma (POAG) is commonest type, affecting 2/3rd of glaucoma patients. POAG is estimated to affect 6.48 million persons. The estimated number with primary angle-closure glaucoma is 2.54 million.

POAG develops gradually and take long time to get detected and require long term treatment with topical prostaglandin analogues (PGF2) which is the most common as well as most widely used drugs. These PGF2 analogues need to be taken for longer time and more prone to develop adverse drug reactions.

Common ADR seen with PG analogues are irritation on instillation, foreign body sensation, dryness of eyes, pain in eye, increased pigmentation of iris, increased eyelash growth, changes in periorbital sulcus and fat. Some ADRs (Adverse Drug Reaction) are explained by the inherent properties of Prostaglandins and those are not explained are because of preservative used in medication and these ADRs can be minimised by using preservative free drug like Tafluprost which are having same efficacy in decreasing IOP.


Keywords


Primary open angle glaucoma, Prostaglandin analogues, Preservative free prostaglandin analogues

Full Text:

PDF

References


Agarwal R, Gupta SK, Agarwal P, Saxena R, Agrawal SS. Current concepts in the pathophysiology of glaucoma. Indian J Ophthalmol 2009;57:257-66.

Gupta N, Weinreb RN. New definitions of glaucoma. Curr Opin Ophthalmol 1997;8:38-41.

What are the types of glaucoma? Internet www.hopkinsmedicine.org/wilmer/gce/book/chapter types_of _glaucoma). Accessed on l5 June 2013.

George R, Ve RS, Vijaya L. Glaucoma in India: estimated burden of disease; J Glaucoma. 2010 Aug;19(6):391-7.

Types of Glaucoma. Available at www.glaucoma.org/glaucoma/types-of-glaucoma.php. Accessed on 5 June 2013.

Jerald A Bell. Primary open angle glaucoma.(emedicine.medscape.com/article/1206147) 29/07/2013.

Kaushik S, Pandav SS, Ram J. Neuroprotection in glaucoma. J Postgrad Med.2003;49:90–5.

Hendrickx KH, van den Enden A, Rasker MT, Hoyng PF. Cumulative incidence of patients with disc hemorrhages in glaucoma and the effect of therapy. Ophthalmology.1994;101:1165–72.

Clark AF, Miggans ST, Wilson K, Browder S, McCartney MD. Cytoskeletal changes in cultured human glaucoma trabecular meshwork cells. J Glaucoma 1995;4:183-8

Lutjen-Drecoll E, Shimizu T, Rohrbach M, Rohen JW. Quantitative analysis of 'plaque material' in the inner- and outer wall of Schlemm's canal in normal- and glaucomatous eyes. Exp Eye Res 1986;42:443-55.

Knepper PA, Goossens W, Hvizd M, Palmberg PF. Glycosaminoglycans of the human trabecular meshwork in primary open-angle glaucoma. Invest Ophthalmol Vis Sci 1986;37:1360-7.

Lutjen-Drecoll E, Rohen JW. Morphology of aqueous outflow pathways in normal and glaucomatous eyes. In: Ritch R, Shields MB, Krupin T, editors. The glaucomas. St. Louis: Mosby Year; 1996. p. 89-123.

Johnson EC, Morrison JC, Farrell S, Deppmeier L, Moore CG, McGinty MR. The effect of chronically elevated intraocular pressure on the rat optic nerve head extracellular matrix. Exp Eye Res 1996;62:663-74.

Pena JD, Taylor AW, Ricard CS, Vidal I, Hernandez MR. Transforming growth factor beta isoforms in humen optic nerve heads. Br J Ophthalmol 1999;83:209-18.

Cordeiro MF. Beyond mitomycin: TGF-beta and wound healing. Prog Retin Eye Res 2002;21:75-89.

Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell 1997;91:439-42.

Li G, Moss SE, Alexander RA, Ali RR, Fitzke FW, Cordeiro MF. Retinal ganglion cell apoptosis in glaucoma is related to intraocular pressure and IOP-induced effects on extracellular matrix. Invest Ophthalmol Vis Sci 2005;46:175-82.

Grossmann J. Molecular mechanisms of "detachment-induced apoptosis-anoikis". Apoptosis 2002;7:247-60.

Yan X, Tezel G, Wax MB, Edward DP. Matrix metalloproteinases and tumor necrosis factor alpha in glaucomatous optic nerve head. Arch Ophthalmol 2000;118:666-73.

Agapova OA, Ricard CS, Salvador-Silva M, Hernandez MR. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human optic nerve head astrocytes. Glia 2001;33:205-16.

Nickells W. Retinal ganglion cell death in glaucoma: t0 he how, the witty and the maybe. J Glaucoma 1996;5:345-56.

Nakazawa T, Nakazawa C, Matsubara A, Noda K, Hisatomi T, She H, et al . Tumor necrosis factor- mediates oligodendrocyte death and delayed retinal ganglion cell loss in a mouse model of glaucoma. J Neurosci2006;26:12633-41.

Wang JJ, Mitchell P, Smith W. Is there an association between migraine headache and open-angle glaucoma? Findings of the Blue Mountains Study. Ophthalmol1997;104:1714-9.

Curseifen C, Wisse M, Curseifen S, Junemann A, Martus P, Korth M. Migraine and tension headache in highpressure and normal-pressure glaucoma. Am J Ophthalmol 2000;129:102-4.

Gass A, Flammer J, Linder L, Romerio SC, Gasser P, Haefeli WE. Inverse correlation between endothelin-1-induced peripheral microvascular vasoconstriction and blood pressure in glaucoma patients. Graefes Arch Clin Exp Ophthalmol 1997;235:634-8.

O'Brien C, Butt Z. Blood flow velocity in the peripheral circulation of glaucoma patients. Ophthalmologica 1999;213:150-3.

Cellini M, Possati GL, Profazio V, Sbrocca M, Caramazza N, Caramazza R. Color Doppler imaging and plasma levels of endothelin-1 in low-tension glaucoma. Acta Ophthalmol Scand 1997;224:11-3.

Noske W, Hensen J, Wiederholt M. Endothelin-like immunoreactivity in aqueous humor of patients with primary open-angle glaucoma and cataract. Graefes Arch Clin Exp Ophthalmol 1997;235:55.

Tezel G, Kass MA, Kolker AE, Becker B, Wax MB. Plasma and aqueous humor endothelin levels in primary open-angle glaucoma. J Glaucoma 1997;6:83-9.

Hollo G, Lakatos P, Farkas K. Cold pressor test and plasma endothelin-1 concentration in primary open-angle and capsular glaucoma. J Glaucoma 1998;7:105-10.

Kedzierski RM, Yanagisawa M. Endothelin system: the doubleedged sword in health and disease. Annu Rev Pharmacol Toxicol 2001;41:851–76.

MacCumber MW, D’Anna SA. Endothelin receptor-binding subtypes in the human retina and choroid. Arch Ophthalmol 1994;112:1231–5.

MacCumber MW, Ross CA, Glaser BM, Snyder SH.Endothelin: visualization of mRNAs by in situ hybridization provides evidence for local action. Proc Natl Acad Sci U S A1989;86:7285–9.

Lepple-Wienhues A, Becker M, Stahl F, et al. Endothelin-like immune reactivity in the aqueous humour and in conditioned medium from cultured ciliary epithelial cells. Curr Eye Res 1992;11:1041–6.

Balwantray C. Chauhan, Endothelin and its potential role in glaucoma; J Ophthalmol 2008;43:356–60.

Ernest JT. Pathogenesis of glaucomatous optic nerve disease. Trans Am Ophthalmol Soc 1975;73:366–88.

Yorio T, Krishnamoorthy R, Prasanna G. Endothelin: Is it a contributor to glaucoma pathophysiology? J Glaucoma 2002;11:259–70.

Prostaglandin - Wikipedia, the free encyclopedia 28/05/2013.

Carol b toris,vikas gulati:the biology,pathology and therapeutic uses of prostaglandins in eye ; clin lipidology 2011;6(5):577-591.

Schlotzer-Schrehardt U, Zenkelm, Nusing RM; Expression And Localization of EP and FP receptor subtypes in human eye; Invest Opthalmol Vis Sci, May 2002;43(5):1475-87.

Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res.1998;67:179–191.

Sagara T, Gaton DD, Lindsey JD, et al. Topical prostaglandin F2alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol. 1999;117:794–801.

Lütjen-Drecoll E, Tamm E. Morphological study of the anterior segment of cynomolgus monkey eyes following treatment with prostaglandin F2 alpha. Exp Eye Res. 1988;47:761–769.

Tamm E, Rittig M, Lütjen-Drecoll E. [Electron microscopy and immunohistochemical studies of the intraocular pressure lowering effect prostaglandin F2 alpha] Fortschr Ophthalmol. 1990;87:623–629.

Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem.1999;274:21491–21494.

Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors:biological actions and therapeutic opportunities. J Cell Sci. 2002;115:3719–3727.

Pang IH, Fleenor DL, Hellberg PE, Stropki K, McCartney MD, Clark AF. Aqueous outflow-enhancing effect of tert-butylhydroquinone: involvement of AP-1 activation and MMP-3 expression. Invest Ophthalmol Vis Sci. 2003;44:3502–3510.

Parshley DE, Bradley JM, Samples JR, Van Buskirk EM, Acott TS.Early changes in matrix metalloproteinases and inhibitors after in vitro laser treatment to the trabecular meshwork. Curr Eye Res.1995;14:537–544.

Hinz B, Rösch S, Ramer R, et al. Latanoprost induces matrix metalloproteinase-1 expression in human nonpigmented ciliary epithelial cells through a cyclooxygenase-2-dependent mechanism. FASEB J. 2005;19:1929–1931.

Thieme H, Schimmat C, Münzer G, et al. Endothelin antagonism: effects of FP receptor agonists prostaglandin F2alpha and fluprostenol on trabecular meshwork contractility. Invest Ophthalmol Vis Sci. 2006;47:938–945.

Carol b toris,vikas gulati:the biology,pathology and therapeutic uses of prostaglandins in eye:ocular therapeutic uses of PG Agonists & antagonists ; clin lipidology 2011;6(5):577-591.

Cory Swymer and Michael W Neville, Tafluprost: The First Preservative-Free Prostaglandin to Treat Open-Angle Glaucoma and Ocular Hypertension; Annals of Pharmacotherapy 2012;46:1506-10.

Unoprostone.Internet(http://www.fda.gov/cder/consumerinfo/druginfo/rescula.htm) 28/05/2013.

Unoproston.Internet(www.rxlist.com/rescula-drug/clinica pharmacology) 28/05/2013.

Chemical structure ofprostaglandin analogue: latanoprost, J Ocul Pharmacol Ther. 2009 December; 25(6): 487–498.

Latanoprost, eyedrop solution.medsafe.Internet (www.medsafe.govt.nz/profs/datasheet/a/arrowlatanoprostdrop)06/06/2013.

Sjöquist B, Stjernschantz J Ocular and systemic pharmacokinetics of latanoprost in humanswww.ncbi.nlm.nih.gov/pubmed/12204697.

Latanoprost ophthalmic solution ;clinical pharmacology.www.rxlist.com/xalatan-drug/clinical-pharmacology 06/06/2013.

59) Chemical structure ofprostaglandin analogue;trovoprost, J Ocul Pharmacol Ther. 2009 December; 25(6): 487–498

Travoprost,Ophthalmic-Solution:0.004%(travoprost)solution.Internate (dailymed.nlm.nih.gov) 06/06/2013.

Trovoprost ophthalmic solution (0.004%). Internet (dailymed.nlm.nih.gov) 06/06/2013.

Wan z Woodward DF, Cornell CL, Fliri HG, Martos JL: Bimatoprost, prostamide activity, and conventional drainage, Invest Ophthalmol Vis Sci. 2007 Sep;48(9):4107-15.

DrugBank: Bimatoprost (DB00905). Internet. (www.drugbank.ca/drugs/DB00905; 06/06/2013.

Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol 2008;53 Suppl1:S93–105.

Albert S. Khouri, MD; Robert D. Fechtner: Lowering IOP With Medical Therapy in Patients With Glaucoma: First-Line Agents Prostaglandin Analogs. Internet (www.medscape.org/viewarticle/580534_2‎)25/06/2013.

Xalatan. Generic Name: latanoprost ophthalmic. Internet(www.drugs.com › Drugs A to Z › Xa › Xalatan‎) 25/06/2013.

Hysite, Eyedrops, solution-Medsafe. Internet (www.medsafe.govt.nz/profs/datasheet/h/Hysiteeyedrops) 25/06/2013.

Kahook MY, Noecker R. Quantitative analysis of conjunctival goblet cells afterchronic application of topical drugs. Adv Ther 2008;25:743-51.

Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol 2008;86:716-26.

Januleviãienò I, Derkaã I, Grybauskiene L, Paulauskaitò R, Gromnickaite R, Kuzmienò L. Effects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patientswith open-angle glaucoma. Clin Ophthalmol (Auckland, NZ)2012;6:103.

Tressler CS, Beatty R, Lemp MA. Preservative use in topical glaucoma medications. Ocul Surf 2011;9:140-58.

David A. Ammar, Robert J. Noecker, Malik Y. Kahook. Effects of Benzalkonium Chloride-Preserved, Polyquad- Preserved, and sofZia-Preserved Topical Glaucoma Medications on Human Ocular Epithelial Cells, Published online: September 30, 2010, Springer Healthcare 2010, 27(11):837-845.

Yam JC, Yuen NS, Chan CW. Bilateral deepening of upperlid sulcus from topical bimatoprost therapy. J Ocul Pharmacol Ther 2009;25:471–472.

Peplinski LS, Albiani Smith K. Deepening of lid sulcus from topical bimatoprost therapy. Optom Vis Sci 2004;81:574–577.

Filippopoulos T, Paula JS, Torun N, Hatton MP, Pasquale LR,Grosskreutz CL. Periorbital changes associated with topical bimatoprost. Ophthal Plast Reconstr Surg 2008;24:302–307.

Park J, Cho HK, Moon JI. Changes to upper eyelid orbital fatfrom use of topical bimatoprost, travoprost, and latanoprost. Jpn J Ophthalmol 2011;55:22–27.

Leonard K. Seibold, David A. Ammar, and Malik Y. Kahook, Acute Effects of Glaucoma Medications and Benzalkonium Chloride On Pre-adipocyte Proliferation and Adipocyte Cytotoxicity In Vitro, Current Eye Research, 38(1), 70–74, 2013.

Horsley MB, Kahook MY. Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients. Clin Ophthalmol. 2009;3:291-295.

Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004;23:490-496.

Pisella PJ, Debbasch C, Hamard P, et al. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci. 2004;45:1360-1368.

Kahook MY, Noecker RJ. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea. 2008;27:339-343.

Rossi GCM, et al. Efficacy and ocular surface tolerability of preservative-free tafluprost 0.0015%: a 6-month,single-blind, observational study on naı¨ve ocular hypertension or glaucoma patients. Expert Opin. Drug Saf. 2012 ;11(4):519-525.

Hannu Uusitalo, Enping Chen, Norbert Pfeiffer,et al, Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication; Acta Ophthalmol. 2010: 88: 329–336.

Cory Swymer and Michael W Neville, Tafluprost: The First Preservative-Free Prostaglandin to Treat Open-Angle Glaucoma and Ocular Hypertension; Annals of Pharmacotherapy 2012;46:1506-10.

Laurie Barclay, MD. FDA Approvals: First Preservative-Free Prostaglandin Eye Drops for Glaucoma. Internet. (www.drugs.com ,preservative free prostaglandin analogue:Tafluprost) 25/06/2013.

Michael V. Boland, Ann-Margret Ervin, David S. Friedman, Henry D. Jampel, etal. Comparative Effectiveness of Treatments for Open-Angle Glaucoma:A Systematic Review, Annals of Internal Medicine on February 19, 2013;158:271-279.

Li N, Chen XM, Zhou Y, Wei ML, Yao X. Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials. Clin Experiment Ophthalmol. 2006;34:755-64.

Zhang WY, Po AL, Dua HS, Azuara-Blanco A. Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension. Br J Ophthalmol. 2001;85:983-90.